September 21, 2018
A leader in the biotech industry, REGENXBIO is developing technologies critical to the success of innovative gene therapy products with the potential to cure a range of devastating diseases. Find out how Chardan enabled the growth of this groundbreaking platform.
A Fruitful Start
First, we helped REGENXBIO management define objectives. Together, we crafted a compelling story to share with institutional investors and venture capital funds during a two-week, Chardan-hosted roadshow. The result: a meaningfully upsized Series D financing of $70.5 million.
Sole Placement Agent
Following the Crossover round financing, Chardan facilitated the formation of the IPO syndicate and through the assisted the book runners in the successful $159.4 million IPO.
Chardan continued to support the company through marketing activities—including European and US roadshows, leadership calls, and KOL events—and acted as a co-manager on their first follow-on.
We've received your information, and we're processing your request.